Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Regulation of Metabolism01:19

Regulation of Metabolism

Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perturbation Analysis of a Prognostic <i>DDX3X</i>-Mediated Gene Expression Signature Identifies the Antimetastatic Potential of Chaetocin in Hepatocellular Carcinoma.

Cells·2023
Same author

RUNX2 and Cancer.

International journal of molecular sciences·2023
Same author

Updated Functional Roles of NAMPT in Carcinogenesis and Therapeutic Niches.

Cancers·2022
Same author

Functional Roles of SPINK1 in Cancers.

International journal of molecular sciences·2021
Same author

Leptin and Cancer: Updated Functional Roles in Carcinogenesis, Therapeutic Niches, and Developments.

International journal of molecular sciences·2021
Same author

Leptin Is Associated with Poor Clinical Outcomes and Promotes Clear Cell Renal Cell Carcinoma Progression.

Biomolecules·2021

Related Experiment Videos

ENO1 as a Central Regulator Linking Metabolic Reprogramming to Tumor Plasticity.

Tsung-Chieh Lin1,2

  • 1Genomic Medicine Core Laboratory, Department of Medical Research and Development, Chang Gung Memorial Hospital, Linkou, Taoyuan City 333, Taiwan.

International Journal of Molecular Sciences
|May 27, 2026
PubMed
Summary

Alpha-enolase (ENO1) is crucial in glycolysis and cancer progression. This review highlights ENO1

Keywords:
ENO1cancer metabolismdrug resistancemetastasispan-cancer analysisprognostic biomarkertumor progression

Related Experiment Videos

Area of Science:

  • Biochemistry
  • Oncology
  • Molecular Biology

Background:

  • Alpha-enolase (ENO1) is a key glycolytic enzyme.
  • Emerging evidence links ENO1 to cancer development and progression.

Purpose of the Study:

  • To review the biological and clinical significance of ENO1 in various cancers.
  • To explore ENO1's role in cancer hallmarks and its potential as a biomarker and therapeutic target.

Main Methods:

  • Literature review of physiological characteristics, expression patterns, and genomic alterations of ENO1.
  • Examination of ENO1's involvement in cancer-related processes.
  • Analysis of prognostic associations in pan-cancer datasets.

Main Results:

  • ENO1 exhibits aberrant expression and genomic alterations in human cancers.
  • ENO1 is implicated in proliferation, apoptosis resistance, stemness, autophagy, metastasis, drug resistance, and angiogenesis.
  • ENO1 expression correlates with patient prognosis across multiple cancer types.

Conclusions:

  • ENO1 is closely associated with malignant progression via metabolic reprogramming and tumor-promoting functions.
  • ENO1 shows potential as a context-dependent biomarker and therapeutic target in specific cancer settings.
  • Further validation is needed to establish ENO1's translational value.